Defeating cancer together: our policy priorities
We believe there are three areas the Government could prioritise to enable cancer research in academic institutions to thrive, and help us on our mission to continue making the discoveries that defeat cancer.
"We need the Government to use all available policy levers to support the sector and help cancer research in UK academic institutions thrive."
- Professor Kristian Helin, Chief Executive, The Institute of Cancer Research
"100 days in - it is vital that this new Parliament comes together to prioritise cancer research. For all of us affected by cancer, research is where hope starts, Parliament can help catalyse this hope"
- Sue Duncombe, Cancer Patient Advocate
Advocacy blog posts
The Charity Research Support Fund: An overlooked, and neglected, lifeline for UK science
Ollie Richards, Advocacy Manager at the ICR, explores how a critical element of the Government's research funding – the Charity Research Support Fund – could be reformed to help support more specialist institutions and universities to do life-saving research.
100 days in – what do we need from the Government to enable cancer research to thrive?
We’re now 100 days into the new Government and the ICR’s Advocacy Manager, Ollie Richards, outlines what academic institutions need the Government to prioritise to help us on our mission to continue making the discoveries that defeat cancer.
Latest ICR News
Study sets out clear recommendations for patient-reported outcomes in early cancer drug trials
New research presents clear guidelines on how patient-reported outcomes (PROs) can be used more effectively in early-stage cancer drug trials, helping ensure that patient experiences meaningfully informed treatment decisions around dosing.
ICR welcomes NICE recommendation of talazoparib for advanced prostate cancer
The Institute of Cancer Research, London, welcomes the decision by the National Institute for Health and Care Excellence (NICE) to recommend the targeted drug talazoparib (trade name Talzenna), in combination with enzalutamide, for adults with prostate cancer that has spread.
Breast cancer blood test can predict treatment response
A blood test can predict how well patients with advanced breast cancer will respond to targeted therapies – before treatment begins, according to new research.